(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Becoming Familiar with an Unknown dialect: My Language Learning Excursion - 25 Morning Schedules That Stimulate Your Day
- 3Reconnecting with an old friend is a story of distance, loss and rediscovery
- 4The most effective method to Look at Medical caretaker Compensations Across Various Clinics
- 56 Famous Cell phone Brands All over The Planet
- Evidence of lost baptismal rite stage uncovered in Byzantine era cathedral near Sea of Galilee
- Hostile to Maturing Skincare Items to Rejuvenate Your Skin
- Figure out How to Advance Space in Your Pre-assembled Home for Upgraded Usefulness
- The Conclusive Manual for Spending plan Travel: Opening Undertakings on a Tight budget
- The Best Cell phone Brands for Tech Lovers
- Figure out How to Use the Experience of a Fender bender Legal counselor for Your Potential benefit
- James Webb Space Telescope watches 'Jekyll and Hyde' galaxy shapeshift into a cosmic monster
- 6 Famous Urban communities for Shopping on the planet
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
